-- Total Net Revenues Up 18% Year-Over-Year --

-- EXPAREL® Net Product Sales Up 15% Year-Over-Year --

-- Conference Call Today at 9 a.m. ET --

 

PARSIPPANY, N.J., Aug. 04, 2016  -- Pacira Pharmaceuticals, Inc. (PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2016.

 

“The second quarter marked another period of double-digit, year-over-year revenue growth as we advanced multiple initiatives to support EXPAREL in the latter half of this year and into 2017,” said Dave Stack, Chief Executive Officer and Chairman of Pacira. “Our aggressive investments in patient outreach and clinical development, as well as commercial and educational programs, are progressing as planned.

Second Quarter 2016 Revenue to be in the range of $9.3 million to $9.5 million, an increase of over 50% versus First Quarter 2016

Second Quarter 2016 U.S. Revenue to be in the range of $7.0 million to $7.2 million, an increase of over 65% versus the First Quarter of 2016

Company modifies its liquidity and revenue covenants under its loan facility

Company to report Second Quarter 2016 Financial Results on August 4, 2016

 

ATLANTA, July 26, 2016 -- Alimera Sciences (ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today pre-announced its revenue for the second quarter of 2016 and also announced certain modifications to its loan facility.

Transaction brings together two market leaders in generics with highly complementary product offerings

Marks a significant step in Nichi-Iko’s international growth strategy through establishment of U.S. platform

 

TOKYO & SCHAUMBURG, Ill.-- Nichi-Iko Pharmaceutical Co., Ltd (TSE:4541) and Sagent Pharmaceuticals, Inc. (SGNT) today announced that they have entered into a definitive merger agreement under which Nichi-Iko will acquire Sagent via an all-cash tender offer (the “Tender Offer”) followed by a second-step merger, for a total consideration of approximately $736 million.

 

This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160710005079/en/

VANCOUVER, BRITISH COLUMBIA--(Jun 20, 2016) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, pleased to announce that it has entered into a definitive agreement for filing two abbreviated new drug submissions (ANDS) with exclusive marketing rights to Canada from an unnamed, manufacturer. The manufacturing company is vertically integrated and manufactures these and other products from active pharmaceutical ingredient (API) to finished dosage forms. The manufacturer has USFDA and EU approved manufacturing facilities.

 

One of these molecules ranks among the top 3 molecules in Canadian generics market in 2015, with the market size of approximately $150 million (source:IMS Health); the other product will become off patent in 2017.